UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Enrolling By Invitation
99 years or below
All
1 participants needed
1 Location
Brief description of study
TBD
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Lymphoma, B-Cell', 'Lymphoma, Non-Hodgkin', 'Leukemia, B-cell', 'Graft Vs Host Disease', 'Solid Tumor']
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 828236
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
